A COMPREHENSIVE EXPLORATION OF ADVANCES IN CERVICAL CANCER TREATMENT: TARGETED THERAPY, RADIOTHERAPY AND CHEMOTHERAPY
Keywords:
cancer, benign, malignant, cervical cancerAbstract
Cancer is a complex group of diseases characterized by the uncontrolled growth and spread of abnormal cells. These cells can invade and destroy normal tissues and can also spread to other parts of the body through the bloodstream and lymphatic system. The development of cancer involves genetic mutations that disrupt the normal regulation of cell growth, leading to the formation of tumors. These tumors are of two types which describe the behaviour of tumor. They are benign and malignant. Malignant tumors can metastasize, or spread into, neighboring tissues, and can also generate new tumors by traveling to far-off regions of the body. Malignant tumors is another term for cancerous tumors, benign tumors do not penetrate or spread to neighboring tissues. Benign tumors typically don’t recur after removal. There exist more than 100 distinct types of cancer, each designated by the specific cell type or organ of origin. Each variation is characterized by unique causal factors, and cancer, being a preventable and treatable ailment, exhibits improved outcomes through early detection via screening. This research paper provides a comprehensive overview of cervical cancer, encompassing its epidemiology, risk factors, and cutting-edge advancements in preventive and therapeutic strategies. Beyond conventional approaches, such as surgery and chemotherapy, the paper examines the efficacy and potential of targeted therapy, radiation therapy, and immunotherapy in combating cervical cancer. These therapeutic strategies offer hopeful paths for individualized treatment, leading to enhanced outcomes for patients.
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A. (2018): Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. – CA: A Cancer Journal for Clinicians 68(6): 394-424.
Burmeister, C.A., Khan, S.F., Schäfer, G., Mbatani, N., Adams, T., Moodley, J., Prince, S. (2022): Cervical cancer therapies: Current challenges and future perspectives. – Tumour Virus Research 13: 14p.
Choi, C.W., Cho, C.K., Yoo, S.Y., Kim, M.S., Yang, K.M., Yoo, H.J., Seo, Y.S., Kang, J.K., Lee, D.H., Lee, K.H., Lee, E.D. (2009): Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. – International Journal of Radiation Oncology* Biology* Physics 74(1): 147-153.
Crosbie, E.J., Einstein, M.H., Franceschi, S., Kitchener, H.C. (2013): Human papillomavirus and cervical cancer. – Lancet [Internet] 382: 889-999.
DeVita, V.T., Lawrence, T.S., Rosenberg, S.A. (2012): Cancer: principles & practice of oncology: primer of the molecular biology of cancer. – Lippincott Williams & Wilkins 2374p.
Eifel, P.J. (2006): Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. – Nature Clinical Practice Oncology 3(5): 248-255.
Eifel, P.J., Klopp, A.H., Berek, J.S., Konstantinopoulos, P.A. (2018): Cancer of the cervix, vagina, and vulva. – In DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. – Wolters Kluwer Health Pharma Solutions (Europe) Ltd. 38p.
Farley, J., Sill, M.W., Birrer, M., Walker, J., Schilder, R.J., Thigpen, J.T., Coleman, R.L., Miller, B.E., Rose, P.G., Lankes, H.A. (2011): Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. – Gynecologic Oncology 121(2): 303-308.
Gadducci, A., Tana, R., Cosio, S., Cionini, L. (2010): Treatment options in recurrent cervical cancer. – Oncology Letters 1(1): 3-11.
Ghebre, R.G., Grover, S., Xu, M.J., Chuang, L.T., Simonds, H. (2017): Cervical cancer control in HIV-infected women: past, present and future. – Gynecologic Oncology Reports 21: 101-108.
Goncalves, A., Fabbro, M., Lhommé, C., Gladieff, L., Extra, J.M., Floquet, A., Chaigneau, L., Carrasco, A.T., Viens, P. (2008): A phase II trial to evaluate gefitinib as second-or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. – Gynecologic Oncology 108(1): 42-46.
Green, J.A., Kirwan, J.M., Tierney, J.F., Symonds, P., Fresco, L., Collingwood, M., Williams, C.J. (2001): Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. – The Lancet 358(9284): 781-786.
Guo, Y., Zhang, D., Li, Y., Wang, Y. (2020): A case of successful maintained pregnancy after neoadjuvant chemotherapy plus radical surgery for stage IB3 cervical cancer diagnosed at 13 weeks. – BMC Pregnancy and Childbirth 20: 1-4.
Hasselle, M.D., Rose, B.S., Kochanski, J.D., Nath, S.K., Bafana, R., Yashar, C.M., Hasan, Y., Roeske, J.C., Mundt, A.J., Mell, L.K. (2011): Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. – International Journal of Radiation Oncology* Biology* Physics 80(5): 1436-1445.
Jain, R.K. (2005): Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. – Science 307(5706): 58-62.
Kashihara, T., Kobayashi, K., Iijima, K., Murakami, N., Yoshida, K., Okuma, K., Nakamura, S., Takahashi, K., Inaba, K., Igaki, H., Nakayama, Y. (2020): A case report of a patient with bulky uterine cervical neoplasm who achieved complete response with “intentional internal high-dose policy” high-dose-rate interstitial brachytherapy. – Medicine 99(27): 4p.
Koh, W.J., Abu-Rustum, N.R., Bean, S., Bradley, K., Campos, S.M., Cho, K.R., Chon, H.S., Chu, C., Clark, R., Cohn, D., Crispens, M.A. (2019): Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. – Journal of the National Comprehensive Cancer Network 17(1): 64-84.
Mackay, H.J., Tinker, A., Winquist, E., Thomas, G., Swenerton, K., Oza, A., Sederias, J., Ivy, P., Eisenhauer, E.A. (2010): A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND. 184. – Gynecologic Oncology 116(2): 163-167.
Markman, M. (2008): The promise and perils of ‘targeted therapy’of advanced ovarian cancer. – Oncology 74(1-2): 1-6.
McCormack, M., Kadalayil, L., Hackshaw, A., Hall-Craggs, M.A., Symonds, R.P., Warwick, V., Simonds, H., Fernando, I., Hammond, M., James, L., Feeney, A. (2013): A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. – British Journal of Cancer 108(12): 2464-2469.
Monk, B.J., Sill, M.W., Burger, R.A., Gray, H.J., Buekers, T.E., Roman, L.D. (2009): Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. – Journal of Clinical Oncology 27(7): 1069-1074.
Muñoz, N., Bosch, F.X., De Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K.V., Snijders, P.J., Meijer, C.J. (2003): Epidemiologic classification of human papillomavirus types associated with cervical cancer. – New England Journal of Medicine 348(6): 518-527.
Park, D.C., Suh, M.J., Yeo, S.G. (2009): Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results. – International Journal of Gynecologic Cancer 19(5): 943-947.
Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., Franceschi, S. (2016): Global burden of cancers attributable to infections in 2012: a synthetic analysis. – The Lancet Global Health 4(9): e609-e616.
Ramirez, P.T., Frumovitz, M., Pareja, R., Lopez, A., Vieira, M., Ribeiro, R., Buda, A., Yan, X., Shuzhong, Y., Chetty, N., Isla, D. (2018): Minimally invasive versus abdominal radical hysterectomy for cervical cancer. – New England Journal of Medicine 379(20): 1895-1904.
Ribeiro, A.A., Costa, M.C., Alves, R.R.F., Villa, L.L., Saddi, V.A., Carneiro, M.A.D.S., Zeferino, L.C., Rabelo-Santos, S.H. (2015): HPV infection and cervical neoplasia: associated risk factors. – Infectious Agents and Cancer 10: 1-7.
Santin, A.D., Sill, M.W., McMeekin, D.S., Leitao Jr, M.M., Brown, J., Sutton, G.P., Van Le, L., Griffin, P., Boardman, C.H. (2011): Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. – Gynecologic Oncology 122(3): 495-500.
Scambia, G., Ferrandina, G., Distefano, M., D'Agostino, G., Benedetti-Panici, P., Mancuso, S. (1998): Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. – Cancer Letters 123(2): 135-139.
Schilder, R.J., Sill, M.W., Lee, Y.C., Mannel, R. (2009): A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. – International Journal of Gynecologic Cancer 19(5): 929-933.
Shen, D.W., Pouliot, L.M., Hall, M.D., Gottesman, M.M. (2012): Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. – Pharmacological Reviews 64(3): 706-721.
Sriplung, H., Singkham, P., Iamsirithaworn, S., Jiraphongsa, C., Bilheem, S. (2014): Success of a cervical cancer screening program: trends in incidence in songkhla, southern Thailand, 1989-2010, and prediction of future incidences to 2030. – Asian Pacific Journal of Cancer Prevention 15(22): 10003-10008.
Tewari, K.S., Sill, M.W., Long III, H.J., Penson, R.T., Huang, H., Ramondetta, L.M., Landrum, L.M., Oaknin, A., Reid, T.J., Leitao, M.M., Michael, H.E. (2014): Improved survival with bevacizumab in advanced cervical cancer. – New England Journal of Medicine 370(8): 734-743.
Thigpen, T., Shingleton, H., Homesley, H., Lagasse, L., Blessing, J. (1981): Cis‐platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. – Cancer 48(4): 899-903.
Vesco, K.K., Whitlock, E.P., Eder, M., Burda, B.U., Senger, C.A., Lutz, K. (2011): Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the US Preventive Services Task Force. – Annals of Internal Medicine 155(10): 698-705.
Viswanathan, A.N., Moughan, J., Small, W., Levenback, C., Iyer, R., Hymes, S., Dicker, A.P., Miller, B., Erickson, B., Gaffney, D.K. (2012): The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective trials 0116 and 0128. – International Journal of Gynecologic Cancer 22(1): 659-664.
Vora, C., Gupta, S. (2018): Targeted therapy in cervical cancer. – ESMO Open 3: 8p.
Yang, J., Cai, H., Xiao, Z.X., Wang, H., Yang, P. (2019): Effect of radiotherapy on the survival of cervical cancer patients: An analysis based on SEER database. – Medicine 98(30): 10p.
World Health Organization (WHO)(2020): Cervical cancer. – WHO Web Portal 6p.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 UDDANTI NAGA SOUMYA SRI, SAMYUKTHA METTA, MIDDE AISHWARYA, GIDDI PRIZLY, CHAKALI KUSUMA, NADINDLA LOKESH
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
